Phase 2 N=85 Amgen 386 for Recurrent Glioblastoma
Glioblastoma Multiforme
Primary: 6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B] — 0.243; 0 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=28 Acamprosate in the Treatment of Pathological Gambling
Pathological Gambling
Primary: The Primary Efficacy Measure Was the Yale-Brown Obsessive Compulsive Scale Modified for PG (YBOCS-PG). — -.985 units on a scale — p=0.05
Phase 2 N=23 Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 — 0…
Phase 2 N=30 A Study of Axitinib in Advanced Carcinoid Tumors
Carcinoid Tumor
Primary: Rate of Progression Free Survival (PFS) — 74.5 percentage of participants
Phase 2 N=29 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Maximum Tolerated Dose of Vorinostat — 500 mg twice daily X 5 days
Phase 2 N=48 Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma
Primary: Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or…
Phase 2 N=124 Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
Alzheimer's Disease
Primary: Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths — 18; 19; 22; 20 Participants
Phase 3 N=562 Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Herpes Zoster
Primary: Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations — 80.4; 0.8 Percentage
Phase 4 N=15 Acute Effect of Exenatide on Brain Glucose Metabolism
Impaired Glucose Tolerance (IGT) · Diabetes
Primary: Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism — 0.14; 0.10 μmol/(ml*min)
Phase 2 N=44 RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Four Cycle Progression-free Survival Rate — 8 Participants
Phase 2 N=270 A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Various Advanced Cancer
Primary: Objective Response Rate Per BIRC Assessment — 19.6 Percent of participants
Phase 2 N=15 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus. — 16 mg/m^2
N/A N=5 Cast vs. Splints for Minimally Displaced Distal Radius Fractures in the Elderly
Radius; Fracture, Lower or Distal End
Primary: Change in Wrist Range of Motion (ROM)
N/A N=30 Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study
Myopia · Hyperopia
Primary: Flap Thickness Accuracy Within the Central Zone at Month 3 Postoperative — 125.8 micrometers
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants